Evidence map›Paper›PMID 39616289›Full record

ArticleEndocrine2025

Association of changes in metabolic syndrome with new-onset and progression of chronic kidney disease.

Naihui Zhao, Yinggen Zhang, Peipei Liu, Xiaofu Zhang, Zihao Zhang, Wenli Ou, Ao Dong, Yanhe Chang, Shuohua Chen, Guodong Wang and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Naihui Zhao *School of Public Health, North China University of Science and Technology, Caofeidian Eco-city, Tangshan, Hebei, China.
Yinggen Zhang *Department of Nuclear Medicine, Kailuan General Hospital, Tangshan, Hebei, China.
Peipei LiuSchool of Public Health, North China University of Science and Technology, Caofeidian Eco-city, Tangshan, Hebei, China.
Xiaofu ZhangHebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research on Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Caofeidian Eco-city, Tangshan, Hebei, China.
Zihao ZhangSchool of Public Health, North China University of Science and Technology, Caofeidian Eco-city, Tangshan, Hebei, China.
Wenli OuSchool of Public Health, North China University of Science and Technology, Caofeidian Eco-city, Tangshan, Hebei, China.
Ao DongSchool of Public Health, North China University of Science and Technology, Caofeidian Eco-city, Tangshan, Hebei, China.
Yanhe ChangDepartment of Nuclear Medicine, Kailuan General Hospital, Tangshan, Hebei, China.
Shuohua ChenDepartment of Cardiology, Kailuan General Hospital, Tangshan, Hebei, China.
Guodong WangDepartment of Cardiology, Kailuan General Hospital, Tangshan, Hebei, China.
Shouling WuDepartment of Cardiology, Kailuan General Hospital, Tangshan, Hebei, China. drwusl@163.com.
Xiuhong YangSchool of Public Health, North China University of Science and Technology, Caofeidian Eco-city, Tangshan, Hebei, China. yangxiuhong@ncst.edu.cn.

Funding

National Natural Science Foundation of China 81970359the project of the high-level group for research and innovation of the School of Public Health, North China University of Science and Technology KYTD202311
6 · The paper itself

Abstract

backgroundMetabolic syndrome (MetS) is an independent risk factor for new-onset and progression of chronic kidney disease (CKD). However, whether changes in MetS are associated with the new-onset CKD and its progression remains unknown.

methodsA total of 36,571 participants from the Kailuan Study were enrolled in this study, including 27,072 without CKD and 9499 with CKD at baseline. According to the changes of MetS, 4 groups were divided as follows: MetS-free group, MetS-recovered group, MetS-developed group, and MetS-persistent group. Cox regression models were used to explore the association of changes in MetS with new-onset and progression of CKD.

resultsDuring a median follow-up of 8.38 years, 3313 cases of new-onset CKD were identified in participants without CKD. Compared with the MetS-free group, the hazard ratio (HR) and 95% confidence interval (95% CI) for new-onset CKD in the MetS-recovered, MetS-developed and MetS-persistent groups was 1.34 (1.18-1.53), 1.46 (1.30-1.63) and 1.85 (1.69-2.02), respectively. Among 9499 participants with CKD, during a median follow-up of 8.18 years, a total of 2305 experienced CKD progression. Compared with the MetS-free group, the HR (95% CI) for CKD progression in each group were 1.05 (0.91-1.22), 1.34 (1.17-1.55) and 1.65 (1.49-1.83), respectively. Furthermore, the association between changes in MetS and new-onset CKD was stronger in younger and middle-aged participants (≤60 years old) compared with older participants.

conclusionsDeveloped MetS and persistent MetS were both risk factors for the new-onset and progression of CKD. Even with recovery from MetS, an association of MetS with kidney damage remained.

Indexed as

Metabolic SyndromeRenal Insufficiency, ChronicAdultAgedDisease ProgressionFemaleFollow-Up StudiesHumansMaleMiddle AgedRisk FactorsChronic kidney diseaseChronic kidney disease progressionCohort studyMetabolic syndrome

Identifiers

PMID39616289

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.